Invivyd, Inc. (IVVD) Stock

Invivyd, Inc., a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, is dedicated to pioneering antibody-based solutions for infectious diseases within the United States. The company's flagship product candidate, adintrevimab, represents a neutralizing antibody currently undergoing Phase 3 clinical trials. Adintrevimab is positioned for both the treatment and prevention of coronavirus disease, underscoring Invivyd's commitment to combatting global health challenges.

Beyond adintrevimab, Invivyd, Inc. maintains a robust pipeline of discovery stage candidates aimed at preventing seasonal influenza, showcasing its proactive approach in addressing prevalent respiratory infections. The company operates strategic collaborations vital to its research efforts, including a partnership with Adimab, LLC for the discovery and optimization of proprietary antibodies. Additionally, Invivyd collaborates with the Scripps Research Institute, focusing on research activities aimed at identifying vaccine candidates for influenza and beta coronaviruses.

Established in 2020 and formerly known as Adagio Therapeutics, Inc., Invivyd, Inc. has swiftly positioned itself as a leader in the biopharmaceutical sector dedicated to advancing innovative solutions in infectious disease treatment and prevention. With a strong foundation in scientific research and strategic partnerships, Invivyd continues to drive forward in its mission to deliver impactful therapies for global public health challenges.